Taxoids

04/01/2010 - "Addition of taxanes to anthracycline based regimens improved the pathological complete response in our patients with breast cancer."
01/01/2007 - "Taxanes and fluoropyrimidines are active in metastatic breast cancer (MBC), and their combination has proven effective in anthracycline-refractory patients. "
09/01/2006 - "The taxanes have been studied extensively and have been proven effective for treating early and advanced breast cancer. "
01/01/2012 - "However, GEICAM 9805 study has shown positive results on DFS in high-risk node-negative breast cancer patients with adjuvant taxanes."
01/01/2011 - "Furthermore, we also demonstrated that patients with high risk, node-negative breast cancer also benefited from taxanes therapy, a result that was not observed in previous studies."

04/01/2013 - "Although taxanes are highly effective in cancer treatment, their use is associated with serious complications attributable to large interindividual variability in pharmacokinetics and a narrow therapeutic window. "
06/01/2013 - "Taxanes are important chemotherapeutic agents with proven efficacy in human cancers, but their use is limited by resistance development. "
01/01/2015 - "Taxanes introduction in the mid 90s leads to significant advancement as well as superlative improvement in the treatment of cancer. "
10/01/2005 - "In contrast, taxanes, agents that stabilize microtubules, are far less effective against the same cancer types. "
06/01/1997 - "The relatively recent introduction of a new class of chemotherapeutic agents--the taxoids--has raised hope of improved survival for patients with advanced or metastatic cancer. "

10/01/2014 - "Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer."
10/01/2012 - "Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer."
09/01/2012 - "To reduce the side effects and improve the efficacy of chemoradiation therapy, taxanes were incorporated into polymeric nanoparticles (PNP), and their synergic effect on radiation therapy in non-small cell lung cancer was evaluated. "
03/15/2011 - "Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models."
01/01/2003 - "Our objective of the present study was to examine the impact of prolonged exposure on the cytotoxicity of taxanes against non-small-cell lung carcinoma (NSCLC) cell lines and the clinical response and outcome of the patients. "

10/01/2005 - "With 177Lu-J591, dose fractionation in combination with taxanes should be considered as an alternative approach to achieve optimal therapeutic efficacy in patients with prostate cancer."
03/01/2010 - "Other trials of ABCB1 genotyping in breast and prostate cancer patients receiving taxanes have shown inconsistent results. "
09/01/2007 - "Although there is a body of knowledge on the mechanisms of action of taxanes and resistance pathways, there are few clinical or translational studies in prostate cancer adequately assessing the modulation of these mechanisms. "
10/01/1999 - "The mechanisms of cytotoxicity of taxanes in prostate cancer are undoubtedly complex and will require considerable additional study to fully understand."
02/15/2015 - "Novel actions of next-generation taxanes benefit advanced stages of prostate cancer."

01/01/2012 - "All studies that examined the efficacy and safety of taxanes administered during pregnancy in ovarian cancer, regardless of sample size, were considered eligible. "
02/01/2014 - "Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer."
04/15/2012 - "Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1."
01/01/2012 - "Taxanes may play a significant role in the treatment of ovarian cancer patients during the 2nd and 3rd trimesters. "
01/01/2012 - "This is the first systematic review to synthesize all available data and evaluate the efficacy and safety of taxanes during pregnancy in ovarian cancer. "